University of Alabama at Birmingham Cancer Center
RecruitingBirmingham, Alabama, 35233, United States
Site contacts (2)
Site Public ContactContactEmail: gingerreeves@uabmc.edu
Mauricio R. EscobarPrincipal investigator
CLINICAL STUDY · NCT06058377
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
RecruitingPhase 3Interventional
Sponsored by National Cancer Institute (NCI)
- Condition
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
- Study locations
- 561 reported sites
- Study updated
- 19 Oct 2026
- Source
- ClinicalTrials.gov
Overall study status is shown above. Individual hospitals may have a different recruitment status.
THE STUDY
About this study
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Full official title
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Detailed description
PRIMARY OBJECTIVE:
I. To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab.
SECONDARY OBJECTIVES:
I. To compare pathologic complete response rates (ypT0/is, ypN0) in participants randomized to standard of care chemotherapy alone versus (vs.) standard of care neoadjuvant chemotherapy concurrent with durvalumab.
II. To compare residual cancer burden distribution between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.
III. To compare distant relapse-free survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.
IV. To compare overall survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.
V. To compare the frequency and severity of toxicities between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab among those who initiate the assigned treatment.
PRIMARY QUALITY OF LIFE (QOL) OBJECTIVES:
I. To compare the change in fatigue (Patient Reported Outcomes Measurement Information System \[PROMIS\] Fatigue) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs. participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline).
II. To compare the change in global physical health (PROMIS Global Health) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline).
SECONDARY QOL OBJECTIVES:
I. To compare the change in fatigue and global physical health experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone during treatment (at 12 weeks from baseline).
II. To compare the changes in global physical health and fatigue subsequent to treatment (at years 1 and 2) between the two randomized study arms.
III. To compare the changes in global mental health (PROMIS Global Health) during active treatment (weeks 12, 20) and subsequent to treatment (at years 1 and 2) between the two randomized study arms.
IV. To compare the severity and frequency of treatment-related symptoms using Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) items (diarrhea, nausea, cough, shortness of breath, rash, and musculoskeletal pain) over time experienced by participants receiving neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone.
BANKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE:
STEP 1: Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2.
STEP 2: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive paclitaxel intravenously (IV) on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive paclitaxel IV on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of cycles 1, 3, and 5. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of cycles 7 and 9. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
All patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at standard of care (SOC) surgery and undergo collection of blood samples throughout the study.
After completion of study treatment, patients are followed until death or 10 years, whichever occurs first.
I. To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab.
SECONDARY OBJECTIVES:
I. To compare pathologic complete response rates (ypT0/is, ypN0) in participants randomized to standard of care chemotherapy alone versus (vs.) standard of care neoadjuvant chemotherapy concurrent with durvalumab.
II. To compare residual cancer burden distribution between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.
III. To compare distant relapse-free survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.
IV. To compare overall survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.
V. To compare the frequency and severity of toxicities between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab among those who initiate the assigned treatment.
PRIMARY QUALITY OF LIFE (QOL) OBJECTIVES:
I. To compare the change in fatigue (Patient Reported Outcomes Measurement Information System \[PROMIS\] Fatigue) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs. participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline).
II. To compare the change in global physical health (PROMIS Global Health) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline).
SECONDARY QOL OBJECTIVES:
I. To compare the change in fatigue and global physical health experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone during treatment (at 12 weeks from baseline).
II. To compare the changes in global physical health and fatigue subsequent to treatment (at years 1 and 2) between the two randomized study arms.
III. To compare the changes in global mental health (PROMIS Global Health) during active treatment (weeks 12, 20) and subsequent to treatment (at years 1 and 2) between the two randomized study arms.
IV. To compare the severity and frequency of treatment-related symptoms using Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) items (diarrhea, nausea, cough, shortness of breath, rash, and musculoskeletal pain) over time experienced by participants receiving neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone.
BANKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE:
STEP 1: Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2.
STEP 2: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive paclitaxel intravenously (IV) on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive paclitaxel IV on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of cycles 1, 3, and 5. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of cycles 7 and 9. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
All patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at standard of care (SOC) surgery and undergo collection of blood samples throughout the study.
After completion of study treatment, patients are followed until death or 10 years, whichever occurs first.
PARTICIPATION
Who may participate
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex eligibility
- All sexes
- Healthy volunteers
- Not accepted
Only the study team can confirm eligibility. The registry criteria below are not a medical recommendation.
Full inclusion and exclusion criteria
Inclusion Criteria:
* STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines
* NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible
* STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer
* NOTE: Participants with inflammatory breast cancer are eligible
* NOTE: Participants with occult (i.e. undetectable) primary breast cancer with axillary nodal involvement are not eligible, as MammaPrint testing has not been validated on tissue obtained from an axillary lymph node
* STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines
* STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer
* STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same breast or synchronous bilateral primary tumors are eligible, however, all tumors that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2 status on at least one of the lesions
* NOTE: Biopsy of multiple lesions in the same breast is not required if the clinical presentation is consistent with a single disease process that is multifocal in nature. However, if there is clinical suspicion of two distinct primary breast malignancies, additional biopsies should be pursued
* STEP 1: REGISTRATION (SCREENING): Participants must have either adequate tissue available to submit on-study or a prior known MammaPrint Index Score that is MP2 status
* Submitting tissue for on-study MammaPrint testing:
* Participants must have a minimum of ten, unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) available from initial tumor biopsy for MammaPrint assessment
* NOTE: Participants must agree to have this tissue submitted to Agendia for MammaPrint Index Scoring and to have subsequent results disclosed to Southwest Oncology Group (SWOG) Cancer Research Network OR
* Submitting prior known MammaPrint Index Score:
* If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy
* NOTE: Participants must agree to have their commercial MammaPrint Index Score disclosed to SWOG Cancer Research Network
* NOTE: Participants with prior known MammaPrint result that is not MP2 status should not be enrolled to either step of this study
* NOTE: Participants enrolling with known MP2 status (i.e. MP already obtained as routine care) must only sign the treatment informed consent form. Screening consent is not required when MP2 status is known prior to study enrollment
* STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy
* STEP 1: REGISTRATION (SCREENING): Participants must be \>= 18 years old at the time of registration
* STEP 1: REGISTRATION (SCREENING): Participants must have body weight \> 30 kg
* STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status of 0-2
* STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* STEP 1: REGISTRATION (SCREENING): Participant must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
* STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
* For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
* STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step 1 Registration
* STEP 2: RANDOMIZATION: Participants must have MammaPrint High Risk 2 result
* For participants submitting tissue for on-study MammaPrint testing:
* Participants must be registered to Step 2: Randomization within 84 calendar days (12 weeks) after receiving an MP2 status from the MammaPrint Index score. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) from initial tumor biopsy OR
* Submitting commercial MammaPrint Index Score:
* If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy
* NOTE: Participants without a MammaPrint High-Risk 2 score must not be registered to Step 2 Randomization
* STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28 days prior to study Step 2: Randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed
* STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
* STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2
* STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within two years prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants must not have active autoimmune disease that has required systemic treatment in the past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) prior to Step 2: Randomization. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
* STEP 2: RANDOMIZATION: Participant must have a complete medical history and physical exam within 28 days prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Platelets \>= 100 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 × institutional ULN (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Participants must have a calculated creatinine clearance \>= 50 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
* STEP 2: RANDOMIZATION: Participants must not have uncontrolled diabetes defined as hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants with history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have an undetectable viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained while on suppressive therapy within 6 months prior to Step 2: Randomization, if indicated
* STEP 2: RANDOMIZATION: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization, if indicated
* STEP 2: RANDOMIZATION: Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process and must have a negative pregnancy test at screening. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy
* STEP 2: RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
* STEP 2: RANDOMIZATION: Participants who can complete questionnaires in English, or Spanish must be offered the opportunity to participate in the Quality of Life study
* STEP 2: RANDOMIZATION: NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
* STEP 2: RANDOMIZATION: Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
* STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines
* NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible
* STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer
* NOTE: Participants with inflammatory breast cancer are eligible
* NOTE: Participants with occult (i.e. undetectable) primary breast cancer with axillary nodal involvement are not eligible, as MammaPrint testing has not been validated on tissue obtained from an axillary lymph node
* STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines
* STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer
* STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same breast or synchronous bilateral primary tumors are eligible, however, all tumors that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2 status on at least one of the lesions
* NOTE: Biopsy of multiple lesions in the same breast is not required if the clinical presentation is consistent with a single disease process that is multifocal in nature. However, if there is clinical suspicion of two distinct primary breast malignancies, additional biopsies should be pursued
* STEP 1: REGISTRATION (SCREENING): Participants must have either adequate tissue available to submit on-study or a prior known MammaPrint Index Score that is MP2 status
* Submitting tissue for on-study MammaPrint testing:
* Participants must have a minimum of ten, unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) available from initial tumor biopsy for MammaPrint assessment
* NOTE: Participants must agree to have this tissue submitted to Agendia for MammaPrint Index Scoring and to have subsequent results disclosed to Southwest Oncology Group (SWOG) Cancer Research Network OR
* Submitting prior known MammaPrint Index Score:
* If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy
* NOTE: Participants must agree to have their commercial MammaPrint Index Score disclosed to SWOG Cancer Research Network
* NOTE: Participants with prior known MammaPrint result that is not MP2 status should not be enrolled to either step of this study
* NOTE: Participants enrolling with known MP2 status (i.e. MP already obtained as routine care) must only sign the treatment informed consent form. Screening consent is not required when MP2 status is known prior to study enrollment
* STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy
* STEP 1: REGISTRATION (SCREENING): Participants must be \>= 18 years old at the time of registration
* STEP 1: REGISTRATION (SCREENING): Participants must have body weight \> 30 kg
* STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status of 0-2
* STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* STEP 1: REGISTRATION (SCREENING): Participant must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
* STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
* For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
* STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step 1 Registration
* STEP 2: RANDOMIZATION: Participants must have MammaPrint High Risk 2 result
* For participants submitting tissue for on-study MammaPrint testing:
* Participants must be registered to Step 2: Randomization within 84 calendar days (12 weeks) after receiving an MP2 status from the MammaPrint Index score. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) from initial tumor biopsy OR
* Submitting commercial MammaPrint Index Score:
* If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy
* NOTE: Participants without a MammaPrint High-Risk 2 score must not be registered to Step 2 Randomization
* STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28 days prior to study Step 2: Randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed
* STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
* STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2
* STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within two years prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants must not have active autoimmune disease that has required systemic treatment in the past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) prior to Step 2: Randomization. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
* STEP 2: RANDOMIZATION: Participant must have a complete medical history and physical exam within 28 days prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Platelets \>= 100 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 × institutional ULN (within 28 days prior to Step 2: Randomization)
* STEP 2: RANDOMIZATION: Participants must have a calculated creatinine clearance \>= 50 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
* STEP 2: RANDOMIZATION: Participants must not have uncontrolled diabetes defined as hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants with history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have an undetectable viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization
* STEP 2: RANDOMIZATION: Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained while on suppressive therapy within 6 months prior to Step 2: Randomization, if indicated
* STEP 2: RANDOMIZATION: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization, if indicated
* STEP 2: RANDOMIZATION: Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process and must have a negative pregnancy test at screening. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy
* STEP 2: RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
* STEP 2: RANDOMIZATION: Participants who can complete questionnaires in English, or Spanish must be offered the opportunity to participate in the Quality of Life study
* STEP 2: RANDOMIZATION: NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
* STEP 2: RANDOMIZATION: Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
NEAR YOU
Study locations worldwide
561 sitesCheck the individual site’s status and contact the listed study team for current availability.
561 sites shown
Katmai Oncology Group
RecruitingAnchorage, Alaska, 99508, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
University of Arizona Cancer Center-Orange Grove Campus
RecruitingTucson, Arizona, 85704, United States
Site contacts (2)
Site Public ContactContactPhone: 520-694-8900
Sima Ehsani ChimehPrincipal investigator
Banner University Medical Center - Tucson
RecruitingTucson, Arizona, 85719, United States
Site contacts (2)
Site Public ContactContactEmail: UACC-IIT@uacc.arizona.edu
Sima Ehsani ChimehPrincipal investigator
University of Arizona Cancer Center-North Campus
RecruitingTucson, Arizona, 85719, United States
Site contacts (2)
Site Public ContactContactEmail: UACC-IIT@uacc.arizona.edu
Sima Ehsani ChimehPrincipal investigator
Mercy Hospital Fort Smith
RecruitingFort Smith, Arkansas, 72903, United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
RecruitingJonesboro, Arkansas, 72401, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
University of Arkansas for Medical Sciences
RecruitingLittle Rock, Arkansas, 72205, United States
Sutter Auburn Faith Hospital
RecruitingAuburn, California, 95602, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
AIS Cancer Center at San Joaquin Community Hospital
RecruitingBakersfield, California, 93301, United States
Alta Bates Summit Medical Center-Herrick Campus
RecruitingBerkeley, California, 94704, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Tower Cancer Research Foundation
RecruitingBeverly Hills, California, 90211, United States
Site contacts (2)
Site Public ContactContactEmail: towercancerresearch@toweroncology.com
Jin Sun L. BitarPrincipal investigator
City of Hope Comprehensive Cancer Center
RecruitingDuarte, California, 91010, United States
Site contacts (2)
Irene M. KangPrincipal investigator
Palo Alto Medical Foundation-Fremont
RecruitingFremont, California, 94538, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RecruitingIrvine, California, 92612, United States
Site contacts (2)
Ritesh ParajuliPrincipal investigator
City of Hope at Irvine Lennar
RecruitingIrvine, California, 92618, United States
City of Hope Antelope Valley
RecruitingLancaster, California, 93534, United States
Site contacts (2)
Irene M. KangPrincipal investigator
Loma Linda University Medical Center
RecruitingLoma Linda, California, 92354, United States
City of Hope at Long Beach Elm
RecruitingLong Beach, California, 90813, United States
The Angeles Clinic and Research Institute - West Los Angeles Office
RecruitingLos Angeles, California, 90025, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Jin Sun L. BitarPrincipal investigator
Cedars-Sinai Medical Center
RecruitingLos Angeles, California, 90048, United States
Site contacts (2)
Jin Sun L. BitarPrincipal investigator
Memorial Medical Center
RecruitingModesto, California, 95355, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
City of Hope Newport Beach
RecruitingNewport Beach, California, 92660, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
RecruitingOrange, California, 92868, United States
Site contacts (2)
Ritesh ParajuliPrincipal investigator
Desert Regional Medical Center
RecruitingPalm Springs, California, 92262, United States
Palo Alto Medical Foundation Health Care
RecruitingPalo Alto, California, 94301, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Huntington Memorial Hospital
RecruitingPasadena, California, 91105, United States
Site contacts (2)
Site Public ContactContactPhone: 626-535-2420
Jin Sun L. BitarPrincipal investigator
Sutter Roseville Medical Center
RecruitingRoseville, California, 95661, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Sutter Medical Center Sacramento
RecruitingSacramento, California, 95816, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
SWOG
RecruitingSacramento, California, 95817, United States
Site contacts (2)
Erin F. CobainContactEmail: ecobain@med.umich.edu
Erin F. CobainPrincipal investigator
Zuckerberg San Francisco General Hospital
Active, not recruitingSan Francisco, California, 94110, United States
Contact details are not published in this record. Check official study record ↗
California Pacific Medical Center-Pacific Campus
RecruitingSan Francisco, California, 94115, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Mills Health Center
RecruitingSan Mateo, California, 94401, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Palo Alto Medical Foundation-Santa Cruz
RecruitingSanta Cruz, California, 95065, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Saint John's Cancer Institute
RecruitingSanta Monica, California, 90404, United States
Providence Medical Foundation - Santa Rosa
RecruitingSanta Rosa, California, 95403, United States
Site contacts (2)
Site Public ContactContactPhone: 707-521-3830
Charles W. DrescherPrincipal investigator
Sutter Pacific Medical Foundation
RecruitingSanta Rosa, California, 95403, United States
Site contacts (2)
Kristie A. BobolisPrincipal investigator
Providence Santa Rosa Memorial Hospital
RecruitingSanta Rosa, California, 95405, United States
Site contacts (2)
Site Public ContactContactPhone: 707-521-3830
Charles W. DrescherPrincipal investigator
City of Hope South Pasadena
RecruitingSouth Pasadena, California, 91030, United States
Site contacts (2)
Irene M. KangPrincipal investigator
Palo Alto Medical Foundation-Sunnyvale
RecruitingSunnyvale, California, 94086, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
Cedars-Sinai Cancer - Tarzana
RecruitingTarzana, California, 91356, United States
Site contacts (2)
Site Public ContactContactPhone: 818-981-3818
Jin Sun L. BitarPrincipal investigator
City of Hope South Bay
RecruitingTorrance, California, 90503, United States
Torrance Memorial Physician Network - Cancer Care
RecruitingTorrance, California, 90505, United States
Site contacts (2)
Jin Sun L. BitarPrincipal investigator
City of Hope Upland
RecruitingUpland, California, 91786, United States
Site contacts (2)
Irene M. KangPrincipal investigator
Sutter Solano Medical Center/Cancer Center
RecruitingVallejo, California, 94589, United States
Site contacts (2)
Site Public ContactContactEmail: clinicalresearch@sutterhealth.org
Kristie A. BobolisPrincipal investigator
UCI Health - Yorba Linda
RecruitingYorba Linda, California, 92886, United States
Site contacts (2)
Ritesh ParajuliPrincipal investigator
UCHealth University of Colorado Hospital
RecruitingAurora, Colorado, 80045, United States
Site contacts (2)
Site Public ContactContactPhone: 720-848-0650
Anthony D. EliasPrincipal investigator
UCHealth - Cherry Creek
RecruitingDenver, Colorado, 80206, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Anthony D. EliasPrincipal investigator
Shaw Cancer Center
RecruitingEdwards, Colorado, 81632, United States
Site contacts (2)
Site Public ContactContactPhone: 970-569-7429
Alexander T. UrquhartPrincipal investigator
Poudre Valley Hospital
RecruitingFort Collins, Colorado, 80524, United States
Site contacts (2)
Site Public ContactContactPhone: 970-297-6150
Anthony D. EliasPrincipal investigator
Cancer Care and Hematology-Fort Collins
RecruitingFort Collins, Colorado, 80528, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Anthony D. EliasPrincipal investigator
UCHealth Greeley Hospital
RecruitingGreeley, Colorado, 80631, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Anthony D. EliasPrincipal investigator
UCHealth Highlands Ranch Hospital
RecruitingHighlands Ranch, Colorado, 80129, United States
Site contacts (2)
Site Public ContactContactPhone: 720-848-0650
Anthony D. EliasPrincipal investigator
UCHealth Lone Tree Health Center
RecruitingLone Tree, Colorado, 80124, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Anthony D. EliasPrincipal investigator
Medical Center of the Rockies
RecruitingLoveland, Colorado, 80538, United States
Site contacts (2)
Site Public ContactContactPhone: 970-203-7083
Anthony D. EliasPrincipal investigator
Smilow Cancer Hospital-Derby Care Center
RecruitingDerby, Connecticut, 06418, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center-Fairfield
RecruitingFairfield, Connecticut, 06824, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center at Glastonbury
RecruitingGlastonbury, Connecticut, 06033, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center at Greenwich
RecruitingGreenwich, Connecticut, 06830, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center - Guilford
RecruitingGuilford, Connecticut, 06437, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center at Saint Francis
RecruitingHartford, Connecticut, 06105, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Yale University
RecruitingNew Haven, Connecticut, 06520, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Yale-New Haven Hospital North Haven Medical Center
RecruitingNorth Haven, Connecticut, 06473, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center at Long Ridge
RecruitingStamford, Connecticut, 06902, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital-Torrington Care Center
RecruitingTorrington, Connecticut, 06790, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center-Trumbull
RecruitingTrumbull, Connecticut, 06611, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital-Waterbury Care Center
RecruitingWaterbury, Connecticut, 06708, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Smilow Cancer Hospital Care Center - Waterford
RecruitingWaterford, Connecticut, 06385, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
Beebe South Coastal Health Campus
RecruitingMillville, Delaware, 19967, United States
Site contacts (2)
Gregory A. MastersPrincipal investigator
Helen F Graham Cancer Center
RecruitingNewark, Delaware, 19713, United States
Site contacts (2)
Gregory A. MastersPrincipal investigator
Medical Oncology Hematology Consultants PA
RecruitingNewark, Delaware, 19713, United States
Site contacts (2)
Gregory A. MastersPrincipal investigator
Beebe Health Campus
RecruitingRehoboth Beach, Delaware, 19971, United States
Site contacts (2)
Gregory A. MastersPrincipal investigator
Sibley Memorial Hospital
RecruitingWashington D.C., District of Columbia, 20016, United States
Site contacts (2)
Cesar A. Santa-MariaPrincipal investigator
Mount Sinai Comprehensive Cancer Center at Aventura
RecruitingAventura, Florida, 33180, United States
Site contacts (2)
Oleg GligichPrincipal investigator
Schulze Family Foundation Cancer Clinic - Bonita Health Center
RecruitingBonita Springs, Florida, 34135, United States
Site contacts (2)
Janine HarewoodPrincipal investigator
Morton Plant Hospital
RecruitingClearwater, Florida, 33756, United States
Site contacts (2)
Site Public ContactContactPhone: 855-314-8646
Robert C. GabordiPrincipal investigator
Regional Cancer Center-Lee Memorial Health System
RecruitingFort Myers, Florida, 33905, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Janine HarewoodPrincipal investigator
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
RecruitingHollywood, Florida, 33021, United States
Site contacts (2)
Adriana M. Milillo-NarainePrincipal investigator
Jupiter Medical Center
Active, not recruitingJupiter, Florida, 33458, United States
Contact details are not published in this record. Check official study record ↗
Mount Sinai Medical Center
RecruitingMiami Beach, Florida, 33140, United States
Site contacts (2)
Oleg GligichPrincipal investigator
Memorial Hospital West
RecruitingPembroke Pines, Florida, 33028, United States
Site contacts (2)
Site Public ContactContactPhone: 954-265-4325
Adriana M. Milillo-NarainePrincipal investigator
Mease Countryside Hospital
RecruitingSafety Harbor, Florida, 34695, United States
Site contacts (2)
Robert C. GabordiPrincipal investigator
Saint Joseph's Hospital/Children's Hospital-Tampa
RecruitingTampa, Florida, 33607, United States
Site contacts (2)
Robert C. GabordiPrincipal investigator
Winter Haven Hospital
RecruitingWinter Haven, Florida, 33881, United States
Site contacts (2)
Robert C. GabordiPrincipal investigator
Grady Health System
RecruitingAtlanta, Georgia, 30303, United States
Site contacts (2)
Site Public ContactContactPhone: 404-778-1868
Demetria Smith-GrazianiPrincipal investigator
Emory University Hospital Midtown
RecruitingAtlanta, Georgia, 30308, United States
Site contacts (2)
Site Public ContactContactPhone: 888-946-7447
Demetria Smith-GrazianiPrincipal investigator
Emory University Hospital/Winship Cancer Institute
RecruitingAtlanta, Georgia, 30322, United States
Site contacts (2)
Site Public ContactContactPhone: 404-778-1868
Demetria Smith-GrazianiPrincipal investigator
Emory Saint Joseph's Hospital
RecruitingAtlanta, Georgia, 30342, United States
Site contacts (2)
Site Public ContactContactPhone: 404-851-7115
Demetria Smith-GrazianiPrincipal investigator
Emory Decatur Hospital
RecruitingDecatur, Georgia, 30033, United States
Site contacts (2)
Demetria Smith-GrazianiPrincipal investigator
Emory Johns Creek Hospital
RecruitingJohns Creek, Georgia, 30097, United States
Site contacts (2)
Demetria Smith-GrazianiPrincipal investigator
Memorial Health University Medical Center
RecruitingSavannah, Georgia, 31404, United States
Site contacts (2)
James J. BurkePrincipal investigator
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
RecruitingSavannah, Georgia, 31405, United States
Site contacts (2)
Alison E. SpellmanPrincipal investigator
Saint Alphonsus Cancer Care Center-Boise
RecruitingBoise, Idaho, 83706, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Saint Luke's Cancer Institute - Boise
RecruitingBoise, Idaho, 83712, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Saint Alphonsus Cancer Care Center-Caldwell
RecruitingCaldwell, Idaho, 83605, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Kootenai Health - Coeur d'Alene
RecruitingCoeur d'Alene, Idaho, 83814, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Saint Luke's Cancer Institute - Fruitland
RecruitingFruitland, Idaho, 83619, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Saint Luke's Cancer Institute - Meridian
RecruitingMeridian, Idaho, 83642, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Saint Alphonsus Cancer Care Center-Nampa
RecruitingNampa, Idaho, 83687, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Saint Luke's Cancer Institute - Nampa
RecruitingNampa, Idaho, 83687, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Kootenai Clinic Cancer Services - Post Falls
RecruitingPost Falls, Idaho, 83854, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Kootenai Clinic Cancer Services - Sandpoint
RecruitingSandpoint, Idaho, 83864, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Advocate Outpatient Center - Aurora
RecruitingAurora, Illinois, 60506, United States
Site contacts (2)
Site Public ContactContactEmail: ncorp@aah.org
Sigrun HallmeyerPrincipal investigator
Advocate Good Shepherd Hospital
RecruitingBarrington, Illinois, 60010, United States
Site contacts (2)
Site Public ContactContactPhone: 847-842-4847
Sigrun HallmeyerPrincipal investigator
Illinois CancerCare-Bloomington
RecruitingBloomington, Illinois, 61704, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Illinois CancerCare-Canton
RecruitingCanton, Illinois, 61520, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
SIH Cancer Institute
RecruitingCarterville, Illinois, 62918, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Illinois CancerCare-Carthage
RecruitingCarthage, Illinois, 62321, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Mount Sinai Hospital Medical Center
RecruitingChicago, Illinois, 60608, United States
Site contacts (2)
Pam G. KhoslaPrincipal investigator
Northwestern University
RecruitingChicago, Illinois, 60611, United States
Site contacts (2)
Patricia A. RobinsonPrincipal investigator
University of Illinois
RecruitingChicago, Illinois, 60612, United States
Advocate Illinois Masonic Medical Center
RecruitingChicago, Illinois, 60657, United States
Site contacts (2)
Site Public ContactContactPhone: 773-296-5360
Sigrun HallmeyerPrincipal investigator
AMG Crystal Lake - Oncology
RecruitingCrystal Lake, Illinois, 60014, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Carle at The Riverfront
RecruitingDanville, Illinois, 61832, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Cancer Care Specialists of Illinois - Decatur
RecruitingDecatur, Illinois, 62526, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Decatur Memorial Hospital
RecruitingDecatur, Illinois, 62526, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Northwestern Medicine Cancer Center Kishwaukee
RecruitingDeKalb, Illinois, 60115, United States
Site contacts (2)
Patricia A. RobinsonPrincipal investigator
Illinois CancerCare-Dixon
RecruitingDixon, Illinois, 61021, United States
Advocate Good Samaritan Hospital
RecruitingDowners Grove, Illinois, 60515, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Carle Physician Group-Effingham
RecruitingEffingham, Illinois, 62401, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Crossroads Cancer Center
RecruitingEffingham, Illinois, 62401, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Advocate Sherman Hospital
RecruitingElgin, Illinois, 60123, United States
Site contacts (2)
Site Public ContactContactPhone: 847-429-2907
Sigrun HallmeyerPrincipal investigator
Illinois CancerCare-Eureka
RecruitingEureka, Illinois, 61530, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Illinois CancerCare-Galesburg
RecruitingGalesburg, Illinois, 61401, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Northwestern Medicine Cancer Center Delnor
RecruitingGeneva, Illinois, 60134, United States
Site contacts (2)
Patricia A. RobinsonPrincipal investigator
Northwestern Medicine Glenview Outpatient Center
RecruitingGlenview, Illinois, 60026, United States
Site contacts (2)
Site Public ContactContactPhone: 312-695-1102
Patricia A. RobinsonPrincipal investigator
Northwestern Medicine Grayslake Outpatient Center
RecruitingGrayslake, Illinois, 60030, United States
Site contacts (2)
Site Public ContactContactPhone: 312-695-1102
Patricia A. RobinsonPrincipal investigator
Advocate South Suburban Hospital
RecruitingHazel Crest, Illinois, 60429, United States
Site contacts (2)
Site Public ContactContactPhone: 708-799-9995
Sigrun HallmeyerPrincipal investigator
Illinois CancerCare-Kewanee Clinic
RecruitingKewanee, Illinois, 61443, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Northwestern Medicine Lake Forest Hospital
RecruitingLake Forest, Illinois, 60045, United States
Site contacts (2)
Site Public ContactContactEmail: cancertrials@northwestern.edu
Patricia A. RobinsonPrincipal investigator
AMG Libertyville - Oncology
RecruitingLibertyville, Illinois, 60048, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Condell Memorial Hospital
RecruitingLibertyville, Illinois, 60048, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Illinois CancerCare-Macomb
RecruitingMacomb, Illinois, 61455, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Carle Physician Group-Mattoon/Charleston
RecruitingMattoon, Illinois, 61938, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Loyola University Medical Center
RecruitingMaywood, Illinois, 60153, United States
Site contacts (2)
Site Public ContactContactPhone: 708-226-4357
Jennifer A. WeissPrincipal investigator
Trinity Medical Center
RecruitingMoline, Illinois, 61265, United States
Site contacts (2)
Site Public ContactContactPhone: 309-779-2000
Pratima ChalasaniPrincipal investigator
SSM Health Good Samaritan
RecruitingMount Vernon, Illinois, 62864, United States
Site contacts (2)
Jay W. CarlsonPrincipal investigator
Carle BroMenn Medical Center
RecruitingNormal, Illinois, 61761, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Carle Cancer Institute Normal
RecruitingNormal, Illinois, 61761, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Cancer Care Center of O'Fallon
RecruitingO'Fallon, Illinois, 62269, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Northwestern Medicine Oak Brook
RecruitingOak Brook, Illinois, 60523, United States
Site contacts (2)
Site Public ContactContactEmail: nctnprogram_rhlccc@northwestern.edu
Patricia A. RobinsonPrincipal investigator
Advocate Christ Medical Center
RecruitingOak Lawn, Illinois, 60453-2699, United States
Site contacts (2)
Site Public ContactContactPhone: 800-323-8622
Sigrun HallmeyerPrincipal investigator
Northwestern Medicine Orland Park
RecruitingOrland Park, Illinois, 60462, United States
Site contacts (2)
Site Public ContactContactEmail: nctnprogram_rhlccc@northwestern.edu
Patricia A. RobinsonPrincipal investigator
Illinois CancerCare-Ottawa Clinic
RecruitingOttawa, Illinois, 61350, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Advocate Lutheran General Hospital
RecruitingPark Ridge, Illinois, 60068, United States
Site contacts (2)
Site Public ContactContactPhone: 847-384-3621
Sigrun HallmeyerPrincipal investigator
Illinois CancerCare-Pekin
RecruitingPekin, Illinois, 61554, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Illinois CancerCare-Peoria
RecruitingPeoria, Illinois, 61615, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Illinois CancerCare-Peru
RecruitingPeru, Illinois, 61354, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Illinois CancerCare-Princeton
RecruitingPrinceton, Illinois, 61356, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
OSF Saint Anthony Medical Center
RecruitingRockford, Illinois, 61108, United States
Site contacts (2)
Site Public ContactContactPhone: 815-227-2633
Shylendra B. SreenivasappaPrincipal investigator
UW Health Carbone Cancer Center Rockford
RecruitingRockford, Illinois, 61114, United States
Site contacts (2)
Fahrettin CovutPrincipal investigator
Memorial Hospital East
RecruitingShiloh, Illinois, 62269, United States
Site contacts (2)
Lindsay L. PetersonPrincipal investigator
Southern Illinois University School of Medicine
RecruitingSpringfield, Illinois, 62702, United States
Springfield Clinic
RecruitingSpringfield, Illinois, 62702, United States
Springfield Memorial Hospital
RecruitingSpringfield, Illinois, 62781, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Carle Cancer Center
RecruitingUrbana, Illinois, 61801, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Northwestern Medicine Cancer Center Warrenville
RecruitingWarrenville, Illinois, 60555, United States
Site contacts (2)
Patricia A. RobinsonPrincipal investigator
Illinois CancerCare - Washington
RecruitingWashington, Illinois, 61571, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Northwest Cancer Center - Crown Point
RecruitingCrown Point, Indiana, 46307, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Northwest Oncology LLC
RecruitingDyer, Indiana, 46311, United States
Site contacts (2)
Site Public ContactContactPhone: 219-924-8178
Pratima ChalasaniPrincipal investigator
Northwest Cancer Center - Hobart
RecruitingHobart, Indiana, 46342, United States
Site contacts (2)
Site Public ContactContactPhone: 219-947-1795
Pratima ChalasaniPrincipal investigator
Saint Mary Medical Center
RecruitingHobart, Indiana, 46342, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Saint Catherine Hospital
RecruitingIndianapolis, Indiana, 46312, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Pratima ChalasaniPrincipal investigator
The Community Hospital
RecruitingMunster, Indiana, 46321, United States
Site contacts (2)
Site Public ContactContactPhone: 219-836-3349
Pratima ChalasaniPrincipal investigator
Women's Diagnostic Center - Munster
RecruitingMunster, Indiana, 46321, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
Northwest Cancer Center - Valparaiso
RecruitingValparaiso, Indiana, 46383, United States
Site contacts (2)
Pratima ChalasaniPrincipal investigator
UI Health Care Mission Cancer and Blood - Ankeny Clinic
RecruitingAnkeny, Iowa, 50023, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-3305
Seema Harichand-HerdtPrincipal investigator
Saint Anthony Regional Hospital
RecruitingCarroll, Iowa, 51401, United States
Site contacts (2)
Seema Harichand-HerdtPrincipal investigator
Mercy Hospital
RecruitingCedar Rapids, Iowa, 52403, United States
Site contacts (2)
Site Public ContactContactPhone: 319-365-4673
Deborah W. WilburPrincipal investigator
Oncology Associates at Mercy Medical Center
RecruitingCedar Rapids, Iowa, 52403, United States
Site contacts (2)
Site Public ContactContactPhone: 319-363-2690
Deborah W. WilburPrincipal investigator
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
RecruitingClive, Iowa, 50325, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-3305
Seema Harichand-HerdtPrincipal investigator
Iowa Methodist Medical Center
RecruitingDes Moines, Iowa, 50309, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-6727
Seema Harichand-HerdtPrincipal investigator
UI Health Care Mission Cancer and Blood - Des Moines Clinic
RecruitingDes Moines, Iowa, 50309, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-3305
Seema Harichand-HerdtPrincipal investigator
Broadlawns Medical Center
RecruitingDes Moines, Iowa, 50314, United States
Site contacts (2)
Site Public ContactContactPhone: 515-282-2200
Seema Harichand-HerdtPrincipal investigator
Mercy Medical Center - Des Moines
RecruitingDes Moines, Iowa, 50314, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-3305
Richard L. DemingPrincipal investigator
UI Health Care Mission Cancer and Blood - Laurel Clinic
RecruitingDes Moines, Iowa, 50314, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-3305
Seema Harichand-HerdtPrincipal investigator
UI Healthcare Mission Cancer and Blood - Fort Dodge
RecruitingFort Dodge, Iowa, 50501, United States
Site contacts (2)
Seema Harichand-HerdtPrincipal investigator
UI Health Care Mission Cancer and Blood - Waukee Clinic
RecruitingWaukee, Iowa, 50263, United States
Site contacts (2)
Site Public ContactContactPhone: 515-241-3305
Seema Harichand-HerdtPrincipal investigator
HaysMed
RecruitingHays, Kansas, 67601, United States
University of Kansas Cancer Center
RecruitingKansas City, Kansas, 66160, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
Lawrence Memorial Hospital
RecruitingLawrence, Kansas, 66044, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
The University of Kansas Cancer Center - Olathe
RecruitingOlathe, Kansas, 66061, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
University of Kansas Cancer Center-Overland Park
RecruitingOverland Park, Kansas, 66210, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
University of Kansas Hospital-Indian Creek Campus
RecruitingOverland Park, Kansas, 66211, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
Salina Regional Health Center
RecruitingSalina, Kansas, 67401, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
University of Kansas Health System Saint Francis Campus
RecruitingTopeka, Kansas, 66606, United States
University of Kansas Hospital-Westwood Cancer Center
RecruitingWestwood, Kansas, 66205, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
Baptist Health Corbin
RecruitingCorbin, Kentucky, 40701, United States
Site contacts (2)
Site Public ContactContactPhone: 859-523-1934
Abigail B. ByrnesPrincipal investigator
CommonSpirit Saint Joseph Medical Center - East Lexington
RecruitingLexington, Kentucky, 40509, United States
Site contacts (2)
Shahzad SiddiquePrincipal investigator
University of Kentucky/Markey Cancer Center
RecruitingLexington, Kentucky, 40536, United States
Site contacts (2)
Site Public ContactContactPhone: 859-257-3379
Rayli Pichardo PernaletePrincipal investigator
Abbeville General Hospital
RecruitingAbbeville, Louisiana, 70510, United States
Site contacts (2)
Site Public ContactContactPhone: 337-898-6413
Michelle M. LochPrincipal investigator
Ochsner LSU Health Monroe Medical Center
RecruitingMonroe, Louisiana, 71202, United States
Site contacts (2)
Sindhu Priya DevarashettyPrincipal investigator
University Medical Center New Orleans
RecruitingNew Orleans, Louisiana, 70112, United States
Site contacts (2)
Michelle M. LochPrincipal investigator
Touro Infirmary
RecruitingNew Orleans, Louisiana, 70115, United States
Site contacts (2)
Michelle M. LochPrincipal investigator
LSU Health Sciences Center at Shreveport
RecruitingShreveport, Louisiana, 71103, United States
Site contacts (2)
Sindhu Priya DevarashettyPrincipal investigator
Ochsner LSU Health - Cancer Treatment Center
RecruitingShreveport, Louisiana, 71106, United States
Site contacts (2)
Site Public ContactContactPhone: 318-813-1406
Sindhu Priya DevarashettyPrincipal investigator
UM Upper Chesapeake Hematology and Oncology - Aberdeen
RecruitingAberdeen, Maryland, 21001, United States
Site contacts (2)
Ashkan BahraniPrincipal investigator
University of Maryland/Greenebaum Cancer Center
RecruitingBaltimore, Maryland, 21201, United States
Site contacts (2)
Site Public ContactContactPhone: 800-888-8823
Katherine H. TkaczukPrincipal investigator
Mercy Medical Center
RecruitingBaltimore, Maryland, 21202, United States
Site contacts (2)
David A. RisebergPrincipal investigator
Sinai Hospital of Baltimore
RecruitingBaltimore, Maryland, 21215, United States
Site contacts (2)
Site Public ContactContactPhone: 410-601-9083
Yvonne L. OttavianoPrincipal investigator
Johns Hopkins University/Sidney Kimmel Cancer Center
RecruitingBaltimore, Maryland, 21287, United States
Site contacts (2)
Cesar A. Santa-MariaPrincipal investigator
UM Upper Chesapeake Medical Center
RecruitingBel Air, Maryland, 21014, United States
UPMC Western Maryland
RecruitingCumberland, Maryland, 21502, United States
FMH James M Stockman Cancer Institute
RecruitingFrederick, Maryland, 21702, United States
UM Baltimore Washington Medical Center/Tate Cancer Center
RecruitingGlen Burnie, Maryland, 21061, United States
Site contacts (2)
Site Public ContactContactPhone: 410-553-8100
Katherine H. TkaczukPrincipal investigator
William E Kahlert Regional Cancer Center/Sinai Hospital
RecruitingWestminster, Maryland, 21157, United States
Site contacts (2)
Site Public ContactContactPhone: 410-871-6400
Yvonne L. OttavianoPrincipal investigator
Beverly Hospital
RecruitingBeverly, Massachusetts, 01915, United States
Site contacts (2)
Site Public ContactContactPhone: 978-922-3000 ext. 2405
Corrine L. ZarwanPrincipal investigator
Tufts Medical Center
RecruitingBoston, Massachusetts, 02111, United States
Site contacts (2)
Don S. DizonPrincipal investigator
Lahey Clinic
RecruitingBurlington, Massachusetts, 01805, United States
Site contacts (2)
Corrine L. ZarwanPrincipal investigator
Addison Gilbert Hospital
RecruitingGloucester, Massachusetts, 01930, United States
Site contacts (2)
Site Public ContactContactPhone: 978-283-4000 ext. 559
Corrine L. ZarwanPrincipal investigator
Lahey Clinic Peabody
RecruitingPeabody, Massachusetts, 01960, United States
Site contacts (2)
Corrine L. ZarwanPrincipal investigator
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
RecruitingAnn Arbor, Michigan, 48106, United States
Site contacts (2)
Elie G. DibPrincipal investigator
University of Michigan Rogel Cancer Center
RecruitingAnn Arbor, Michigan, 48109, United States
Site contacts (2)
Erin F. CobainPrincipal investigator
Bronson Battle Creek
RecruitingBattle Creek, Michigan, 49017, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
RecruitingBrighton, Michigan, 48114, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Trinity Health Medical Center - Brighton
RecruitingBrighton, Michigan, 48114, United States
Site contacts (2)
Elie G. DibPrincipal investigator
University of Michigan - Brighton Center for Specialty Care
RecruitingBrighton, Michigan, 48116, United States
Henry Ford Cancer Institute-Downriver
RecruitingBrownstown, Michigan, 48183, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
RecruitingCanton, Michigan, 48188, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Trinity Health Medical Center - Canton
RecruitingCanton, Michigan, 48188, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Caro Cancer Center
SuspendedCaro, Michigan, 48723, United States
Contact details are not published in this record. Check official study record ↗
Chelsea Hospital
RecruitingChelsea, Michigan, 48118, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
RecruitingChelsea, Michigan, 48118, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Hematology Oncology Consultants-Clarkston
RecruitingClarkston, Michigan, 48346, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford Macomb Hospital-Clinton Township
RecruitingClinton Township, Michigan, 48038, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Corewell Health Dearborn Hospital
RecruitingDearborn, Michigan, 48124, United States
Henry Ford Medical Center-Fairlane
RecruitingDearborn, Michigan, 48126, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Wayne State University/Karmanos Cancer Institute
RecruitingDetroit, Michigan, 48201, United States
Site contacts (2)
Jailan ElayoubiPrincipal investigator
Henry Ford Hospital
RecruitingDetroit, Michigan, 48202, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Henry Ford Health Saint John Hospital
RecruitingDetroit, Michigan, 48236, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford River District Hospital
RecruitingEast China Township, Michigan, 48054, United States
Site contacts (2)
Elie G. DibPrincipal investigator
OSF Saint Francis Hospital and Medical Group
RecruitingEscanaba, Michigan, 49829, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Weisberg Cancer Treatment Center
RecruitingFarmington Hills, Michigan, 48334, United States
Site contacts (2)
Jailan ElayoubiPrincipal investigator
Corewell Health Farmington Hills Hospital
SuspendedFarmington Hills, Michigan, 48336, United States
Contact details are not published in this record. Check official study record ↗
Cancer Hematology Centers - Flint
RecruitingFlint, Michigan, 48503, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Genesee Hematology Oncology PC
SuspendedFlint, Michigan, 48503, United States
Contact details are not published in this record. Check official study record ↗
Genesys Hurley Cancer Institute
RecruitingFlint, Michigan, 48503, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Hurley Medical Center
RecruitingFlint, Michigan, 48503, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
RecruitingGrand Rapids, Michigan, 49503, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Trinity Health Grand Rapids Hospital
RecruitingGrand Rapids, Michigan, 49503, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford Saint John Hospital - Van Elslander
RecruitingGrosse Pointe Woods, Michigan, 48236, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Allegiance Health
RecruitingJackson, Michigan, 49201, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Bronson Methodist Hospital
RecruitingKalamazoo, Michigan, 49007, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
West Michigan Cancer Center
RecruitingKalamazoo, Michigan, 49007, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Karmanos Cancer Institute at McLaren Greater Lansing
RecruitingLansing, Michigan, 48910, United States
Site contacts (2)
Jailan ElayoubiPrincipal investigator
University of Michigan Health - Sparrow Lansing
RecruitingLansing, Michigan, 48912, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Trinity Health Saint Mary Mercy Livonia Hospital
RecruitingLivonia, Michigan, 48154, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford Saint John Hospital - Macomb Medical
RecruitingMacomb, Michigan, 48044, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Schoolcraft Memorial Hospital
RecruitingManistique, Michigan, 49854, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Trinity Health Muskegon Hospital
RecruitingMuskegon, Michigan, 49444, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Corewell Health Lakeland Hospitals - Niles Hospital
RecruitingNiles, Michigan, 49120, United States
Site contacts (2)
Site Public ContactContactPhone: 616-391-1230
Kathleen Y. ButlerPrincipal investigator
Cancer and Hematology Centers of Western Michigan - Norton Shores
RecruitingNorton Shores, Michigan, 49444, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford Health Providence Novi Hospital
RecruitingNovi, Michigan, 48374, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Henry Ford Medical Center-Columbus
RecruitingNovi, Michigan, 48377, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Trinity Health Saint Joseph Mercy Oakland Hospital
RecruitingPontiac, Michigan, 48341, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Corewell Health Reed City Hospital
RecruitingReed City, Michigan, 49677, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Corewell Health William Beaumont University Hospital
RecruitingRoyal Oak, Michigan, 48073, United States
MyMichigan Medical Center Saginaw
RecruitingSaginaw, Michigan, 48601, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Oncology Hematology Associates of Saginaw Valley PC
SuspendedSaginaw, Michigan, 48604, United States
Contact details are not published in this record. Check official study record ↗
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
RecruitingSaint Joseph, Michigan, 49085, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
RecruitingSaint Joseph, Michigan, 49085, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Henry Ford Health Providence Southfield Hospital
RecruitingSouthfield, Michigan, 48075, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
MyMichigan Medical Center Tawas
RecruitingTawas City, Michigan, 48764, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Munson Medical Center
RecruitingTraverse City, Michigan, 49684, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Corewell Health Beaumont Troy Hospital
RecruitingTroy, Michigan, 48085, United States
Henry Ford Health Warren Hospital
RecruitingWarren, Michigan, 48093, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford Warren Hospital - GLCMS
RecruitingWarren, Michigan, 48093, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Henry Ford West Bloomfield Hospital
RecruitingWest Bloomfield, Michigan, 48322, United States
Site contacts (2)
Haythem Y. AliPrincipal investigator
Saint Mary's Oncology/Hematology Associates of West Branch
SuspendedWest Branch, Michigan, 48661, United States
Contact details are not published in this record. Check official study record ↗
Henry Ford Wyandotte Hospital
RecruitingWyandotte, Michigan, 48192, United States
University of Michigan Health - West
RecruitingWyoming, Michigan, 49519, United States
Site contacts (2)
Kathleen Y. ButlerPrincipal investigator
Huron Gastroenterology PC
RecruitingYpsilanti, Michigan, 48106, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
RecruitingYpsilanti, Michigan, 48197, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Essentia Health Saint Joseph's Medical Center
RecruitingBrainerd, Minnesota, 56401, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Minnesota Oncology - Burnsville
RecruitingBurnsville, Minnesota, 55337, United States
Site contacts (2)
David M. KingPrincipal investigator
Minnesota Oncology Hematology PA-Chaska
RecruitingChaska, Minnesota, 55318, United States
Site contacts (2)
David M. KingPrincipal investigator
Mercy Hospital
RecruitingCoon Rapids, Minnesota, 55433, United States
Site contacts (2)
David M. KingPrincipal investigator
Essentia Health - Deer River Clinic
RecruitingDeer River, Minnesota, 56636, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Essentia Health Cancer Center
RecruitingDuluth, Minnesota, 55805, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Saint Luke's Hospital of Duluth
RecruitingDuluth, Minnesota, 55805, United States
Site contacts (2)
Homam AlkaiedPrincipal investigator
Fairview Southdale Hospital
RecruitingEdina, Minnesota, 55435, United States
Site contacts (2)
David M. KingPrincipal investigator
Minnesota Oncology - Edina
RecruitingEdina, Minnesota, 55435, United States
Site contacts (2)
David M. KingPrincipal investigator
Essentia Health Hibbing Clinic
RecruitingHibbing, Minnesota, 55746, United States
Saint John's Hospital - Healtheast
RecruitingMaplewood, Minnesota, 55109, United States
Site contacts (2)
David M. KingPrincipal investigator
Abbott-Northwestern Hospital
RecruitingMinneapolis, Minnesota, 55407, United States
Site contacts (2)
David M. KingPrincipal investigator
Hennepin County Medical Center
RecruitingMinneapolis, Minnesota, 55415, United States
Site contacts (2)
David M. KingPrincipal investigator
North Memorial Medical Health Center
RecruitingRobbinsdale, Minnesota, 55422, United States
Site contacts (2)
David M. KingPrincipal investigator
Park Nicollet Clinic - Saint Louis Park
RecruitingSaint Louis Park, Minnesota, 55416, United States
Site contacts (2)
David M. KingPrincipal investigator
Regions Hospital
RecruitingSaint Paul, Minnesota, 55101, United States
Site contacts (2)
David M. KingPrincipal investigator
United Hospital
RecruitingSaint Paul, Minnesota, 55102, United States
Site contacts (2)
David M. KingPrincipal investigator
Essentia Health Sandstone
RecruitingSandstone, Minnesota, 55072, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Saint Francis Regional Medical Center
RecruitingShakopee, Minnesota, 55379, United States
Site contacts (2)
David M. KingPrincipal investigator
Lakeview Hospital
RecruitingStillwater, Minnesota, 55082, United States
Site contacts (2)
David M. KingPrincipal investigator
Essentia Health Virginia Clinic
RecruitingVirginia, Minnesota, 55792, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Ridgeview Medical Center
RecruitingWaconia, Minnesota, 55387, United States
Site contacts (2)
David M. KingPrincipal investigator
Minnesota Oncology Hematology PA-Woodbury
RecruitingWoodbury, Minnesota, 55125, United States
Site contacts (2)
David M. KingPrincipal investigator
Baptist Memorial Hospital and Cancer Center-Golden Triangle
RecruitingColumbus, Mississippi, 39705, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Baptist Cancer Center-Grenada
RecruitingGrenada, Mississippi, 38901, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Baptist Memorial Hospital and Cancer Center-Union County
RecruitingNew Albany, Mississippi, 38652, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Baptist Memorial Hospital and Cancer Center-Oxford
RecruitingOxford, Mississippi, 38655, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Baptist Memorial Hospital and Cancer Center-Desoto
RecruitingSouthhaven, Mississippi, 38671, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Mercy Oncology and Hematology - Clayton-Clarkson
RecruitingBallwin, Missouri, 63011, United States
Saint Francis Medical Center
RecruitingCape Girardeau, Missouri, 63703, United States
Site contacts (2)
Bryan A. FallerPrincipal investigator
Siteman Cancer Center at Saint Peters Hospital
RecruitingCity of Saint Peters, Missouri, 63376, United States
Site contacts (2)
Lindsay L. PetersonPrincipal investigator
MU Health - University Hospital/Ellis Fischel Cancer Center
RecruitingColumbia, Missouri, 65212, United States
Siteman Cancer Center at West County Hospital
RecruitingCreve Coeur, Missouri, 63141, United States
Site contacts (2)
Lindsay L. PetersonPrincipal investigator
Parkland Health Center - Farmington
RecruitingFarmington, Missouri, 63640, United States
MU Health Care Goldschmidt Cancer Center
Active, not recruitingJefferson City, Missouri, 65109, United States
Contact details are not published in this record. Check official study record ↗
University Health Truman Medical Center
RecruitingKansas City, Missouri, 64108, United States
University of Kansas Cancer Center - Briarcliff
RecruitingKansas City, Missouri, 64116, United States
University of Kansas Cancer Center - North
RecruitingKansas City, Missouri, 64154, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
University of Kansas Cancer Center - Lee's Summit
RecruitingLee's Summit, Missouri, 64064, United States
Site contacts (2)
Priyanka SharmaPrincipal investigator
University of Kansas Cancer Center at North Kansas City Hospital
SuspendedNorth Kansas City, Missouri, 64116, United States
Contact details are not published in this record. Check official study record ↗
Sainte Genevieve County Memorial Hospital
RecruitingSainte Genevieve, Missouri, 63670, United States
CoxHealth South Hospital
RecruitingSpringfield, Missouri, 65807, United States
Washington University School of Medicine
RecruitingSt Louis, Missouri, 63110, United States
Site contacts (2)
Lindsay L. PetersonPrincipal investigator
Mercy Hospital South
RecruitingSt Louis, Missouri, 63128, United States
Site contacts (2)
Jay W. CarlsonPrincipal investigator
Siteman Cancer Center-South County
RecruitingSt Louis, Missouri, 63129, United States
Site contacts (2)
Lindsay L. PetersonPrincipal investigator
Missouri Baptist Medical Center
RecruitingSt Louis, Missouri, 63131, United States
Siteman Cancer Center at Christian Hospital
RecruitingSt Louis, Missouri, 63136, United States
Site contacts (2)
Lindsay L. PetersonPrincipal investigator
Mercy Hospital Saint Louis
RecruitingSt Louis, Missouri, 63141, United States
Missouri Baptist Sullivan Hospital
RecruitingSullivan, Missouri, 63080, United States
Community Hospital of Anaconda
RecruitingAnaconda, Montana, 59711, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Billings Clinic Cancer Center
RecruitingBillings, Montana, 59101, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Bozeman Health Deaconess Hospital
RecruitingBozeman, Montana, 59715, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Benefis Sletten Cancer Institute
RecruitingGreat Falls, Montana, 59405, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
Community Medical Center
RecruitingMissoula, Montana, 59804, United States
Site contacts (2)
John M. SchallenkampPrincipal investigator
OptumCare Cancer Care at Charleston
SuspendedLas Vegas, Nevada, 89102, United States
Contact details are not published in this record. Check official study record ↗
OptumCare Cancer Care at Fort Apache
SuspendedLas Vegas, Nevada, 89183, United States
Contact details are not published in this record. Check official study record ↗
Renown Regional Medical Center
RecruitingReno, Nevada, 89502, United States
Site contacts (2)
Lee S. SchwartzbergPrincipal investigator
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
RecruitingLebanon, New Hampshire, 03756, United States
Site contacts (2)
Muhammad Z. AfzalPrincipal investigator
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
RecruitingElizabeth, New Jersey, 07207, United States
Site contacts (2)
Site Public ContactContactPhone: 908-994-8000
Mridula A. GeorgePrincipal investigator
Hackettstown Medical Center
RecruitingHackettstown, New Jersey, 07840, United States
The Cancer Institute of New Jersey Hamilton
RecruitingHamilton, New Jersey, 08690, United States
Site contacts (2)
Site Public ContactContactPhone: 609-631-6946
Mridula A. GeorgePrincipal investigator
Jersey City Medical Center
RecruitingJersey City, New Jersey, 07302, United States
Site contacts (2)
Mridula A. GeorgePrincipal investigator
Monmouth Medical Center Southern Campus
RecruitingLakewood, New Jersey, 08701, United States
Site contacts (2)
Mridula A. GeorgePrincipal investigator
Monmouth Medical Center
RecruitingLong Branch, New Jersey, 07740, United States
Site contacts (2)
Mridula A. GeorgePrincipal investigator
Morristown Medical Center
RecruitingMorristown, New Jersey, 07960, United States
Rutgers Cancer Institute of New Jersey
RecruitingNew Brunswick, New Jersey, 08903, United States
Site contacts (2)
Site Public ContactContactPhone: 732-235-7356
Mridula A. GeorgePrincipal investigator
Rutgers New Jersey Medical School
RecruitingNewark, New Jersey, 07101, United States
Site contacts (2)
Site Public ContactContactPhone: 732-235-7356
Mridula A. GeorgePrincipal investigator
Newark Beth Israel Medical Center
RecruitingNewark, New Jersey, 07112, United States
Site contacts (2)
Mridula A. GeorgePrincipal investigator
Newton Medical Center
RecruitingNewton, New Jersey, 07860, United States
Chilton Medical Center
RecruitingPompton, New Jersey, 07444, United States
Robert Wood Johnson University Hospital Somerset
RecruitingSomerville, New Jersey, 08876, United States
Site contacts (2)
Mridula A. GeorgePrincipal investigator
Overlook Hospital
RecruitingSummit, New Jersey, 07902, United States
Community Medical Center
RecruitingToms River, New Jersey, 08755, United States
Site contacts (2)
Mridula A. GeorgePrincipal investigator
NYU Langone Hospital - Brooklyn
RecruitingBrooklyn, New York, 11220, United States
Site contacts (2)
Douglas MarksPrincipal investigator
The Cancer Institute at Saint Francis Hospital
RecruitingEast Hills, New York, 11548, United States
Site contacts (2)
Rajasree RoyPrincipal investigator
Glens Falls Hospital
Active, not recruitingGlens Falls, New York, 12801, United States
Contact details are not published in this record. Check official study record ↗
NYU Langone Hospital - Long Island
RecruitingMineola, New York, 11501, United States
Site contacts (2)
Douglas MarksPrincipal investigator
Northern Westchester Hospital
RecruitingMount Kisco, New York, 10549, United States
Site contacts (2)
Meekoo DharPrincipal investigator
Mount Sinai Chelsea
RecruitingNew York, New York, 10011, United States
Site contacts (2)
Paula KleinPrincipal investigator
Laura and Isaac Perlmutter Cancer Center at NYU Langone
RecruitingNew York, New York, 10016, United States
Site contacts (2)
Site Public ContactContactEmail: CancerTrials@nyulangone.org
Douglas MarksPrincipal investigator
Mount Sinai West
RecruitingNew York, New York, 10019, United States
Site contacts (2)
Paula KleinPrincipal investigator
Mount Sinai Hospital
RecruitingNew York, New York, 10029, United States
Site contacts (2)
Paula KleinPrincipal investigator
Manhattan Eye Ear and Throat Hospital
RecruitingNew York, New York, 10065, United States
Lenox Hill Hospital
RecruitingNew York, New York, 10075, United States
Upstate Cancer Center at Oswego
RecruitingOswego, New York, 13126, United States
Site contacts (2)
Sam BenjaminPrincipal investigator
Phelps Memorial Hospital Center
RecruitingSleepy Hollow, New York, 10591, United States
The Philips Family Cancer Center
RecruitingSouthampton, New York, 11968, United States
Site contacts (2)
Site Public ContactContactPhone: 631-638-7400
Anna AndrzejczykPrincipal investigator
Staten Island University Hospital
RecruitingStaten Island, New York, 10305, United States
Stony Brook University Medical Center
RecruitingStony Brook, New York, 11794, United States
Site contacts (2)
Site Public ContactContactPhone: 800-862-2215
Anna AndrzejczykPrincipal investigator
State University of New York Upstate Medical University
RecruitingSyracuse, New York, 13210, United States
SUNY Upstate Medical Center-Community Campus
RecruitingSyracuse, New York, 13215, United States
Upstate Cancer Center at Verona
RecruitingVerona, New York, 13478, United States
Site contacts (2)
Sam BenjaminPrincipal investigator
Good Samaritan University Hospital
RecruitingWest Islip, New York, 11795, United States
Dickstein Cancer Treatment Center
RecruitingWhite Plains, New York, 10601, United States
Site contacts (2)
Yael S. ZackPrincipal investigator
UNC Health Cancer Care Cary
RecruitingCary, North Carolina, 27518, United States
Site contacts (2)
Site Public ContactContactPhone: 919-784-2500Email: CancCtrOncologyClinicalResearch@unchealth.unc.edu
Yara AbdouPrincipal investigator
UNC Lineberger Comprehensive Cancer Center
RecruitingChapel Hill, North Carolina, 27599, United States
Site contacts (2)
Yara AbdouPrincipal investigator
Southeastern Medical Oncology Center-Clinton
RecruitingClinton, North Carolina, 28328, United States
Site contacts (2)
Samer S. KasbariPrincipal investigator
UNC Health Cancer Care Garner
RecruitingGarner, North Carolina, 27529, United States
Site contacts (2)
Site Public ContactContactPhone: 919-784-2500Email: CancCtrOncologyClinicalResearch@unchealth.unc.edu
Yara AbdouPrincipal investigator
Southeastern Medical Oncology Center-Goldsboro
RecruitingGoldsboro, North Carolina, 27534, United States
Site contacts (2)
Samer S. KasbariPrincipal investigator
University of North Carolina-Hillsborough Campus
RecruitingHillsborough, North Carolina, 27278, United States
Site contacts (2)
Yara AbdouPrincipal investigator
Southeastern Medical Oncology Center-Jacksonville
RecruitingJacksonville, North Carolina, 28546, United States
Site contacts (2)
Samer S. KasbariPrincipal investigator
UNC Health Cancer Care Raleigh
RecruitingRaleigh, North Carolina, 27607, United States
Site contacts (2)
Site Public ContactContactPhone: 919-784-2500Email: CancCtrOncologyClinicalResearch@unchealth.unc.edu
Yara AbdouPrincipal investigator
UNC Health Cancer Care Wakefield
RecruitingRaleigh, North Carolina, 27614, United States
Site contacts (2)
Site Public ContactContactPhone: 919-784-2500Email: CancCtrOncologyClinicalResearch@unchealth.unc.edu
Yara AbdouPrincipal investigator
Essentia Health Cancer Center-South University Clinic
RecruitingFargo, North Dakota, 58103, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Miami Valley Hospital South
RecruitingCenterville, Ohio, 45459, United States
Site contacts (2)
Jhansi L. KoduriPrincipal investigator
MetroHealth Medical Center
RecruitingCleveland, Ohio, 44109, United States
Site contacts (2)
Joseph AttallahPrincipal investigator
Ohio State University Comprehensive Cancer Center
RecruitingColumbus, Ohio, 43210, United States
Site contacts (2)
Dionisia QuirogaPrincipal investigator
Columbus Oncology and Hematology Associates Inc
RecruitingColumbus, Ohio, 43214, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Riverside Methodist Hospital
RecruitingColumbus, Ohio, 43214, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Grant Medical Center
RecruitingColumbus, Ohio, 43215, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Doctors Hospital
RecruitingColumbus, Ohio, 43228, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Miami Valley Hospital
RecruitingDayton, Ohio, 45409, United States
Site contacts (2)
Jhansi L. KoduriPrincipal investigator
Premier Blood and Cancer Center
RecruitingDayton, Ohio, 45409, United States
Site contacts (2)
Site Public ContactContactPhone: 937-276-8320
Jhansi L. KoduriPrincipal investigator
Miami Valley Hospital North
RecruitingDayton, Ohio, 45415, United States
Site contacts (2)
Jhansi L. KoduriPrincipal investigator
Delaware Health Center-Grady Cancer Center
RecruitingDelaware, Ohio, 43015, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Grady Memorial Hospital
RecruitingDelaware, Ohio, 43015, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Columbus Oncology and Hematology Associates
RecruitingDublin, Ohio, 43016, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Dublin Methodist Hospital
RecruitingDublin, Ohio, 43016, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
Atrium Medical Center-Middletown Regional Hospital
RecruitingFranklin, Ohio, 45005-1066, United States
Site contacts (2)
Jhansi L. KoduriPrincipal investigator
Miami Valley Cancer Care and Infusion
RecruitingGreenville, Ohio, 45331, United States
Site contacts (2)
Site Public ContactContactPhone: 937-569-7515
Jhansi L. KoduriPrincipal investigator
OhioHealth Mansfield Hospital
RecruitingMansfield, Ohio, 44903, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
OhioHealth Marion General Hospital
RecruitingMarion, Ohio, 43302, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
OhioHealth Pickerington Methodist Hospital
RecruitingPickerington, Ohio, 43147, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
ProMedica Flower Hospital
RecruitingSylvania, Ohio, 43560, United States
Site contacts (2)
Feng JiangPrincipal investigator
Upper Valley Medical Center
RecruitingTroy, Ohio, 45373, United States
Site contacts (2)
Jhansi L. KoduriPrincipal investigator
OhioHealth Westerville Medical Campus/Westerville Cancer Center
RecruitingWesterville, Ohio, 43082, United States
Site contacts (2)
Anitha S. NallariPrincipal investigator
University of Oklahoma Health Sciences Center
RecruitingOklahoma City, Oklahoma, 73104, United States
Site contacts (2)
Wajeeha RazaqPrincipal investigator
Mercy Hospital Oklahoma City
RecruitingOklahoma City, Oklahoma, 73120, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
SuspendedTulsa, Oklahoma, 74146, United States
Contact details are not published in this record. Check official study record ↗
Saint Charles Health System
RecruitingBend, Oregon, 97701, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Legacy Mount Hood Medical Center
RecruitingGresham, Oregon, 97030, United States
Providence Hood River Memorial Hospital
RecruitingHood River, Oregon, 97031, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Providence Newberg Medical Center
RecruitingNewberg, Oregon, 97132, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Saint Alphonsus Cancer Care Center-Ontario
RecruitingOntario, Oregon, 97914, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Providence Willamette Falls Medical Center
RecruitingOregon City, Oregon, 97045, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Legacy Good Samaritan Hospital and Medical Center
RecruitingPortland, Oregon, 97210, United States
Site contacts (2)
Mei DongPrincipal investigator
Providence Portland Medical Center
RecruitingPortland, Oregon, 97213, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Providence Saint Vincent Medical Center
RecruitingPortland, Oregon, 97225, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Legacy Meridian Park Hospital
RecruitingTualatin, Oregon, 97062, United States
Lehigh Valley Hospital-Cedar Crest
RecruitingAllentown, Pennsylvania, 18103, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Saint Luke's Cancer Center - Allentown
RecruitingAllentown, Pennsylvania, 18104, United States
UPMC-Heritage Valley Health System Beaver
RecruitingBeaver, Pennsylvania, 15009, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Saint Luke's University Hospital-Bethlehem Campus
RecruitingBethlehem, Pennsylvania, 18015, United States
Lehigh Valley Hospital - Muhlenberg
RecruitingBethlehem, Pennsylvania, 18017, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Bryn Mawr Hospital
RecruitingBryn Mawr, Pennsylvania, 19010, United States
Site contacts (2)
Arezoo GhaneiePrincipal investigator
UPMC Hillman Cancer Center at Butler Health System
RecruitingButler, Pennsylvania, 16001, United States
Site contacts (2)
Julia FoldiPrincipal investigator
UPMC Hillman Cancer Center - Passavant - Cranberry
RecruitingCranberry Township, Pennsylvania, 16066, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Geisinger Medical Center
RecruitingDanville, Pennsylvania, 17822, United States
Site contacts (2)
Jennifer R. CollinsPrincipal investigator
Geisinger Cancer Center Dickson City
RecruitingDickson City, Pennsylvania, 18519, United States
Site contacts (2)
Jennifer R. CollinsPrincipal investigator
Pocono Medical Center
RecruitingEast Stroudsburg, Pennsylvania, 18301, United States
Site contacts (2)
Elie G. DibPrincipal investigator
Saint Luke's Hospital-Anderson Campus
RecruitingEaston, Pennsylvania, 18045, United States
Site contacts (2)
Maria HafezPrincipal investigator
UPMC Hillman Cancer Center Erie
RecruitingErie, Pennsylvania, 16505, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Saint Vincent Hospital
RecruitingErie, Pennsylvania, 16544, United States
UPMC Cancer Centers - Arnold Palmer Pavilion
RecruitingGreensburg, Pennsylvania, 15601, United States
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
RecruitingHarrisburg, Pennsylvania, 17109, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Lehigh Valley Hospital-Hazleton
RecruitingHazleton, Pennsylvania, 18201, United States
Site contacts (2)
Elie G. DibPrincipal investigator
IRMC Cancer Center
RecruitingIndiana, Pennsylvania, 15701, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Jefferson Hospital
RecruitingJefferson Hills, Pennsylvania, 15025, United States
Site contacts (2)
Casey A. MoffaPrincipal investigator
UPMC-Johnstown/John P. Murtha Regional Cancer Center
RecruitingJohnstown, Pennsylvania, 15901, United States
Geisinger Medical Oncology-Lewisburg
RecruitingLewisburg, Pennsylvania, 17837, United States
Site contacts (2)
Jennifer R. CollinsPrincipal investigator
Yolanda G Barco Oncology Institute
RecruitingMeadville, Pennsylvania, 16335, United States
Site contacts (2)
Casey A. MoffaPrincipal investigator
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
RecruitingMechanicsburg, Pennsylvania, 17050, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Riddle Memorial Hospital
RecruitingMedia, Pennsylvania, 19063, United States
Site contacts (2)
Arezoo GhaneiePrincipal investigator
Forbes Hospital
RecruitingMonroeville, Pennsylvania, 15146, United States
UPMC Hillman Cancer Center - Monroeville
RecruitingMonroeville, Pennsylvania, 15146, United States
Site contacts (2)
Julia FoldiPrincipal investigator
UPMC Hillman Cancer Center in Coraopolis
RecruitingMoon Township, Pennsylvania, 15108, United States
Site contacts (2)
Julia FoldiPrincipal investigator
Arnold Palmer Cancer Center Medical Oncology Norwin
RecruitingN. Huntingdon, Pennsylvania, 15642, United States
Site contacts (2)
Julia FoldiPrincipal investigator
UPMC Cancer Center-Natrona Heights
RecruitingNatrona Heights, Pennsylvania, 15065, United States
Paoli Memorial Hospital
RecruitingPaoli, Pennsylvania, 19301, United States
Site contacts (2)
Arezoo GhaneiePrincipal investigator
Allegheny General Hospital
RecruitingPittsburgh, Pennsylvania, 15212, United States
UPMC-Magee Womens Hospital
RecruitingPittsburgh, Pennsylvania, 15213, United States
UPMC-Saint Margaret
RecruitingPittsburgh, Pennsylvania, 15215, United States
UPMC Hillman Cancer Center
RecruitingPittsburgh, Pennsylvania, 15232, United States
UPMC-Passavant Hospital
RecruitingPittsburgh, Pennsylvania, 15237, United States
UPMC-Saint Clair Hospital Cancer Center
RecruitingPittsburgh, Pennsylvania, 15243, United States
Saint Luke's Hospital - Upper Bucks Campus
RecruitingQuakertown, Pennsylvania, 18951, United States
Community Medical Center
RecruitingScranton, Pennsylvania, 18510, United States
Site contacts (2)
Jennifer R. CollinsPrincipal investigator
UPMC Cancer Center at UPMC Northwest
RecruitingSeneca, Pennsylvania, 16346, United States
Saint Luke's Hospital - Monroe Campus
RecruitingStroudsburg, Pennsylvania, 18360, United States
Site contacts (2)
Maria HafezPrincipal investigator
UPMC Cancer Center-Washington
RecruitingWashington, Pennsylvania, 15301, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Julia FoldiPrincipal investigator
UPMC West Mifflin-Cancer Center Jefferson
RecruitingWest Mifflin, Pennsylvania, 15122, United States
Wexford Health and Wellness Pavilion
RecruitingWexford, Pennsylvania, 15090, United States
Site contacts (2)
Site Public ContactContactEmail: Dawnmarie.DeFazio@ahn.org
Casey A. MoffaPrincipal investigator
Geisinger Wyoming Valley/Henry Cancer Center
RecruitingWilkes-Barre, Pennsylvania, 18711, United States
Site contacts (2)
Jennifer R. CollinsPrincipal investigator
Divine Providence Hospital
RecruitingWilliamsport, Pennsylvania, 17754, United States
Site contacts (2)
Site Public ContactContactEmail: protocols@swog.org
Julia FoldiPrincipal investigator
Lankenau Medical Center
RecruitingWynnewood, Pennsylvania, 19096, United States
Site contacts (2)
Arezoo GhaneiePrincipal investigator
UPMC Memorial
RecruitingYork, Pennsylvania, 17408, United States
Women and Infants Hospital
RecruitingProvidence, Rhode Island, 02905, United States
Site contacts (2)
Site Public ContactContactPhone: 401-274-1122
William M. SikovPrincipal investigator
Smilow Cancer Hospital Care Center - Westerly
RecruitingWesterly, Rhode Island, 02891, United States
Site contacts (2)
Mariya RozenblitPrincipal investigator
MUSC Health - Bluffton Medical Pavilion
RecruitingBluffton, South Carolina, 29910, United States
Site contacts (2)
Abirami SivapiragasamPrincipal investigator
Saint Joseph's/Candler - Bluffton Campus
RecruitingBluffton, South Carolina, 29910, United States
Site contacts (2)
Alison E. SpellmanPrincipal investigator
Prisma Health Cancer Institute - Spartanburg
RecruitingBoiling Springs, South Carolina, 29316, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Roper Hospital
RecruitingCharleston, South Carolina, 29401, United States
Site contacts (2)
Gene B. SaylorsPrincipal investigator
Charleston Oncology - Roper
RecruitingCharleston, South Carolina, 29403, United States
Site contacts (2)
Gene B. SaylorsPrincipal investigator
Bon Secours Saint Francis Hospital
RecruitingCharleston, South Carolina, 29414, United States
Site contacts (2)
Gene B. SaylorsPrincipal investigator
Charleston Oncology - Saint Francis
RecruitingCharleston, South Carolina, 29414, United States
Site contacts (2)
Gene B. SaylorsPrincipal investigator
Medical University of South Carolina
RecruitingCharleston, South Carolina, 29425, United States
Site contacts (2)
Abirami SivapiragasamPrincipal investigator
Prisma Health Cancer Institute - Easley
RecruitingEasley, South Carolina, 29640, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Tidelands Georgetown Memorial Hospital
RecruitingGeorgetown, South Carolina, 29440, United States
Site contacts (2)
Abirami SivapiragasamPrincipal investigator
Prisma Health Cancer Institute - Butternut
RecruitingGreenville, South Carolina, 29605, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Prisma Health Cancer Institute - Faris
RecruitingGreenville, South Carolina, 29605, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Prisma Health Greenville Memorial Hospital
RecruitingGreenville, South Carolina, 29605, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Prisma Health Cancer Institute - Eastside
RecruitingGreenville, South Carolina, 29615, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Prisma Health Cancer Institute - Greer
RecruitingGreer, South Carolina, 29650, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
South Carolina Cancer Specialists PC
RecruitingHilton Head Island, South Carolina, 29926-3827, United States
Site contacts (2)
Alison E. SpellmanPrincipal investigator
Prisma Health Cancer Institute - Seneca
RecruitingSeneca, South Carolina, 29672, United States
Site contacts (2)
Joseph J. StephensonPrincipal investigator
Baptist Memorial Hospital and Cancer Center-Collierville
RecruitingCollierville, Tennessee, 38017, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Covenant Health Cancer Centers
RecruitingKnoxville, Tennessee, 37916, United States
Covenant Health Cancer Centers - West
RecruitingKnoxville, Tennessee, 37932, United States
Baptist Memorial Hospital and Cancer Center-Memphis
RecruitingMemphis, Tennessee, 38120, United States
Site contacts (2)
Ryan A. YatesPrincipal investigator
Covenant Health Oncology Group - Oak Ridge
RecruitingOak Ridge, Tennessee, 37830, United States
UT MD Anderson - The Woodlands
RecruitingConroe, Texas, 77384, United States
Site contacts (2)
Rachel M. LaymanPrincipal investigator
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
RecruitingHouston, Texas, 77030, United States
Site contacts (2)
Ahmed ElkhananyPrincipal investigator
Ben Taub General Hospital
RecruitingHouston, Texas, 77030, United States
UT MD Anderson Cancer Center
RecruitingHouston, Texas, 77030, United States
Site contacts (2)
Rachel M. LaymanPrincipal investigator
UT MD Anderson - West Houston
RecruitingHouston, Texas, 77079, United States
Site contacts (2)
Rachel M. LaymanPrincipal investigator
UT MD Anderson - League City
RecruitingLeague City, Texas, 77573, United States
Site contacts (2)
Rachel M. LaymanPrincipal investigator
University of Texas Health Science Center at San Antonio
RecruitingSan Antonio, Texas, 78229, United States
Site contacts (2)
Kate I. LathropPrincipal investigator
UT MD Anderson - Sugar Land
RecruitingSugar Land, Texas, 77478, United States
Site contacts (2)
Rachel M. LaymanPrincipal investigator
Hematology Oncology Associates of Fredericksburg Inc
RecruitingFredericksburg, Virginia, 22408, United States
Site contacts (2)
Masey M. RossPrincipal investigator
Bon Secours Memorial Regional Medical Center
RecruitingMechanicsville, Virginia, 23116, United States
Site contacts (2)
William J. IrvinPrincipal investigator
Bon Secours Saint Francis Medical Center
RecruitingMidlothian, Virginia, 23114, United States
Site contacts (2)
William J. IrvinPrincipal investigator
Bon Secours Saint Mary's Hospital
RecruitingRichmond, Virginia, 23226, United States
Site contacts (2)
William J. IrvinPrincipal investigator
Virginia Cancer Institute
RecruitingRichmond, Virginia, 23229, United States
Site contacts (2)
Masey M. RossPrincipal investigator
VCU Massey Cancer Center at Stony Point
RecruitingRichmond, Virginia, 23235, United States
Site contacts (2)
Site Public ContactContactEmail: ctoclinops@vcu.edu
Masey M. RossPrincipal investigator
VCU Massey Comprehensive Cancer Center
RecruitingRichmond, Virginia, 23298, United States
Site contacts (2)
Masey M. RossPrincipal investigator
VCU Community Memorial Health Center
RecruitingSouth Hill, Virginia, 23970, United States
Site contacts (2)
Site Public ContactContactEmail: nemer.elmouallem@vcuhealth.org
Masey M. RossPrincipal investigator
Swedish Cancer Institute-Edmonds
RecruitingEdmonds, Washington, 98026, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Swedish Cancer Institute-Issaquah
RecruitingIssaquah, Washington, 98029, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Kadlec Clinic Hematology and Oncology
RecruitingKennewick, Washington, 99336, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Providence Regional Cancer System-Lacey
RecruitingLacey, Washington, 98503, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Swedish Medical Center-First Hill
RecruitingSeattle, Washington, 98122, United States
Site contacts (2)
Charles W. DrescherPrincipal investigator
Northwest Medical Specialties PLLC
RecruitingTacoma, Washington, 98405, United States
Site contacts (2)
Francis M. SenecalPrincipal investigator
Legacy Cancer Institute Medical Oncology and Day Treatment
RecruitingVancouver, Washington, 98684, United States
Site contacts (2)
Site Public ContactContactEmail: oncologyresearch@lhs.org
Mei DongPrincipal investigator
Legacy Salmon Creek Hospital
RecruitingVancouver, Washington, 98686, United States
Vandalia Health/CAMC Institute for Academic Medicine
RecruitingCharleston, West Virginia, 25304, United States
Site contacts (2)
Ahmed A. KhalidPrincipal investigator
West Virginia University Healthcare
RecruitingMorgantown, West Virginia, 26506, United States
Site contacts (2)
Bei JiangPrincipal investigator
Aspirus Cancer Care-Antigo-Volm Cancer Center
RecruitingAntigo, Wisconsin, 54409, United States
Site contacts (2)
Andrew J. HuangPrincipal investigator
ThedaCare Regional Cancer Center
RecruitingAppleton, Wisconsin, 54911, United States
Site contacts (2)
Shannon SchmidtPrincipal investigator
Duluth Clinic Ashland
RecruitingAshland, Wisconsin, 54806, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Aurora Cancer Care-Southern Lakes VLCC
RecruitingBurlington, Wisconsin, 53105, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aurora Saint Luke's South Shore
RecruitingCudahy, Wisconsin, 53110, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Marshfield Medical Center-EC Cancer Center
RecruitingEau Claire, Wisconsin, 54701, United States
Site contacts (2)
Dean A. DelmastroPrincipal investigator
Aurora Health Care Germantown Health Center
RecruitingGermantown, Wisconsin, 53022, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aurora Cancer Care-Grafton
RecruitingGrafton, Wisconsin, 53024, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Bellin Memorial Hospital
RecruitingGreen Bay, Wisconsin, 54301, United States
Site contacts (2)
Site Public ContactContactPhone: 920-435-8326
Srinandan GuntupalliPrincipal investigator
Saint Vincent Hospital Cancer Center Green Bay
RecruitingGreen Bay, Wisconsin, 54301, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Saint Vincent Hospital Cancer Center at Saint Mary's
RecruitingGreen Bay, Wisconsin, 54303, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Aurora BayCare Medical Center
RecruitingGreen Bay, Wisconsin, 54311, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Mercyhealth Hospital and Cancer Center - Janesville
RecruitingJanesville, Wisconsin, 53548, United States
Site contacts (2)
Emily G. RobinsonPrincipal investigator
University of Wisconsin Carbone Cancer Center - Johnson Creek
RecruitingJohnson Creek, Wisconsin, 53038, United States
Site contacts (2)
Rubina QamarPrincipal investigator
Aurora Cancer Care-Kenosha South
RecruitingKenosha, Wisconsin, 53142, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
RecruitingMadison, Wisconsin, 53718, United States
Site contacts (2)
Rubina QamarPrincipal investigator
University of Wisconsin Carbone Cancer Center - University Hospital
RecruitingMadison, Wisconsin, 53792, United States
Site contacts (2)
Rubina QamarPrincipal investigator
Aurora Bay Area Medical Group-Marinette
RecruitingMarinette, Wisconsin, 54143, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Marshfield Medical Center-Marshfield
RecruitingMarshfield, Wisconsin, 54449, United States
Site contacts (2)
Dean A. DelmastroPrincipal investigator
Aspirus Medford Hospital
RecruitingMedford, Wisconsin, 54451, United States
Site contacts (2)
Andrew J. HuangPrincipal investigator
Froedtert Menomonee Falls Hospital
RecruitingMenomonee Falls, Wisconsin, 53051, United States
Site contacts (2)
Site Public ContactContactPhone: 262-257-5100
Sailaja KamarajuPrincipal investigator
Aurora Cancer Care-Milwaukee
RecruitingMilwaukee, Wisconsin, 53209, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aurora Saint Luke's Medical Center
RecruitingMilwaukee, Wisconsin, 53215, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Medical College of Wisconsin
RecruitingMilwaukee, Wisconsin, 53226, United States
Site contacts (2)
Site Public ContactContactPhone: 414-805-3666
Sailaja KamarajuPrincipal investigator
Aurora Sinai Medical Center
RecruitingMilwaukee, Wisconsin, 53233, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Marshfield Medical Center - Minocqua
RecruitingMinocqua, Wisconsin, 54548, United States
Site contacts (2)
Dean A. DelmastroPrincipal investigator
ThedaCare Regional Medical Center - Neenah
RecruitingNeenah, Wisconsin, 54956, United States
Site contacts (2)
Shannon SchmidtPrincipal investigator
Drexel Town Square Health Center
RecruitingOak Creek, Wisconsin, 53154, United States
Site contacts (2)
Site Public ContactContactPhone: 414-805-0505
Sailaja KamarajuPrincipal investigator
Saint Vincent Hospital Cancer Center at Oconto Falls
RecruitingOconto Falls, Wisconsin, 54154, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Vince Lombardi Cancer Clinic - Oshkosh
RecruitingOshkosh, Wisconsin, 54904, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aurora Cancer Care-Racine
RecruitingRacine, Wisconsin, 53406, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
RecruitingRhinelander, Wisconsin, 54501, United States
Site contacts (2)
Andrew J. HuangPrincipal investigator
Marshfield Medical Center-Rice Lake
RecruitingRice Lake, Wisconsin, 54868, United States
Site contacts (2)
Dean A. DelmastroPrincipal investigator
ThedaCare Cancer Care - Shawano
RecruitingShawano, Wisconsin, 54166, United States
Site contacts (2)
Shannon SchmidtPrincipal investigator
Saint Vincent Hospital Cancer Center at Sheboygan
RecruitingSheboygan, Wisconsin, 53081, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Vince Lombardi Cancer Clinic-Sheboygan
RecruitingSheboygan, Wisconsin, 53081, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Essentia Health-Spooner Clinic
RecruitingSpooner, Wisconsin, 54801, United States
Site contacts (2)
Bret E. FridayPrincipal investigator
Aspirus Cancer Care - Stevens Point
RecruitingStevens Point, Wisconsin, 54481, United States
Site contacts (2)
Andrew J. HuangPrincipal investigator
Marshfield Medical Center-River Region at Stevens Point
RecruitingStevens Point, Wisconsin, 54482, United States
Site contacts (2)
Dean A. DelmastroPrincipal investigator
Saint Vincent Hospital Cancer Center at Sturgeon Bay
RecruitingSturgeon Bay, Wisconsin, 54235-1495, United States
Site contacts (2)
Matthew L. RyanPrincipal investigator
Aurora Medical Center in Summit
RecruitingSummit, Wisconsin, 53066, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Essentia Health Saint Mary's Hospital - Superior
RecruitingSuperior, Wisconsin, 54880, United States
Vince Lombardi Cancer Clinic-Two Rivers
RecruitingTwo Rivers, Wisconsin, 54241, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aspirus Cancer Care-Wausau
RecruitingWausau, Wisconsin, 54401, United States
Aurora Cancer Care-Milwaukee West
RecruitingWauwatosa, Wisconsin, 53226, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Aurora West Allis Medical Center
RecruitingWest Allis, Wisconsin, 53227, United States
Site contacts (2)
Sigrun HallmeyerPrincipal investigator
Froedtert West Bend Hospital/Kraemer Cancer Center
RecruitingWest Bend, Wisconsin, 53095, United States
Site contacts (2)
Site Public ContactContactPhone: 414-805-0505
Sailaja KamarajuPrincipal investigator
Marshfield Medical Center - Weston
RecruitingWeston, Wisconsin, 54476, United States
Site contacts (2)
Dean A. DelmastroPrincipal investigator
Aspirus Cancer Care - Wisconsin Rapids
RecruitingWisconsin Rapids, Wisconsin, 54494, United States
Doctors Cancer Center
RecruitingManati, 00674, Puerto Rico
Site contacts (2)
Site Public ContactContactPhone: 787-621-4397
Luis J. Santos ReyesPrincipal investigator
Centro Comprensivo de Cancer de UPR
RecruitingSan Juan, 00927, Puerto Rico
Site contacts (2)
Luis J. Santos ReyesPrincipal investigator
PROncology
RecruitingSan Juan, 00927, Puerto Rico
Site contacts (2)
Luis J. Santos ReyesPrincipal investigator
No centres match this search. Try another hospital, city, state or country.
WHAT IS BEING STUDIED
Treatments and study groups
Interventions
Biospecimen Collection
Undergo optional collection of tissue and/or blood
Study groups: Step 2, Arm 1 (chemotherapy), Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Cyclophosphamide
Given IV
Study groups: Step 2, Arm 1 (chemotherapy), Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Frindovyx, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719
Doxorubicin
Given IV
Study groups: Step 2, Arm 1 (chemotherapy), Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin
Durvalumab
Given IV
Study groups: Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736
Genetic Testing
Undergo MammaPrint testing
Study groups: Step 1 (MammaPrint testing)
Other names: Genetic Analysis, Genetic Examination, Genetic Test
Mammography
Undergo mammography
Study groups: Step 2, Arm 1 (chemotherapy), Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: MG
Paclitaxel
Given IV
Study groups: Step 2, Arm 1 (chemotherapy), Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
Quality-of-Life Assessment
Ancillary studies
Study groups: Step 2, Arm 1 (chemotherapy), Step 2, Arm 2 (chemotherapy, durvalumab)
Other names: Quality of Life Assessment
Study groups
Step 1 (MammaPrint testing)
Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2
Interventions: Other: Genetic Testing
Step 2, Arm 1 (chemotherapy)
Patients receive paclitaxel IV on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery and undergo collection of blood samples throughout the study.
Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery and undergo collection of blood samples throughout the study.
Interventions: Procedure: Biospecimen Collection, Drug: Cyclophosphamide, Drug: Doxorubicin, Procedure: Mammography, Drug: Paclitaxel, Other: Quality-of-Life Assessment
Step 2, Arm 2 (chemotherapy, durvalumab)
Patients receive paclitaxel IV on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of cycles 1, 3, and 5. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of cycles 7 and 9. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery and undergo collection of blood samples throughout the study.
Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery and undergo collection of blood samples throughout the study.
Interventions: Procedure: Biospecimen Collection, Drug: Cyclophosphamide, Drug: Doxorubicin, Biological: Durvalumab, Procedure: Mammography, Drug: Paclitaxel, Other: Quality-of-Life Assessment
RESEARCH DETAILS
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomized
- Study model
- Sequential
- Masking
- None (open label)
- Enrolment
- 3,680 participants · Estimated
TIMELINE & MEASURES
Dates and outcomes
- Study started
- 27 Nov 2023 · Actual
- Primary completion
- 31 May 2032 · Estimated
- Study completion
- 31 May 2032 · Estimated
- First registered
- 28 Sep 2023 · Actual
- Last registry update
- 19 Oct 2026 · Actual
- Status last verified
- Aug 2026
Primary outcomes (1)
Breast cancer event-free survival (BC-EFS)
Defined as the earliest occurrence of any of the following events: Local-regional or distant progression during neoadjuvant therapy or local/regional, or distant invasive breast tumor recurrence post-surgery, invasive ipsilateral breast tumor recurrence, new invasive contralateral breast cancer, or death from any cause. The primary analysis of BC-EFS is a log-rank test between the treatment arms with stratification by the three stratification factors. Additionally, Cox regression will be used to estimate the treatment hazard ratio and 95% confidence interval including the three stratification variables as terms in the model. Kaplan-Meier graphs will show BC-EFS descriptively over time and provide 5-year estimates and 95% confidence intervals. A forest plot will show whether the treatment effect varies over the stratification variables and other selected factors.
Time frame: Up to 10 years after completion of study treatment
Secondary outcomes (4)
Pathologic complete response (pCR) rates
Defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast and specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (ypT0/Tis ypN0). At the completion of all treatment and surgery for all enrolled participants, there will be a comparison of pCR rates between the treatment arms. pCR rates will be compared by a test of two proportions followed by logistic regression to estimate the odds ratio after adjustment for the stratification factors.
Time frame: Up to 10 years after completion of study treatment
Residual cancer burden (RCB)
Defined as a continuous measure of the extent of residual cancer after neoadjuvant chemotherapy that combines the largest diameter of the cancer in the breast, the tumor cell cellularity of the cancer, and the largest diameter and number of involved axillary lymph nodes into a single RCB score. RCB will be analyzed by comparing RCB 2-3 to RCB 0-1.
Time frame: Up to 10 years after completion of study treatment
Distant relapse-free survival (DRFS)
Analyses will be performed using log-rank testing, Cox regression, and Kaplan-Meier estimation.
Time frame: Time from date of randomization (2nd Registration) to date of invasive distant disease recurrence or death due to any cause, assessed up to 10 years after completion of study treatment
Overall survival (OS)
Analyses will be performed using log-rank testing, Cox regression, and Kaplan-Meier estimation. Will also be conducted at alpha = 0.05 (2-sided).
Time frame: Time from date of randomization (2nd Registration) to date of death due to any cause, assessed up to 10 years after completion of study treatment
STUDY TEAM
Sponsor and contacts
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- Nih
- Collaborators
- Not reported
- Organisation study ID
- NCI-2023-04566
Central study contacts
No central contact is currently reported. Check the site contacts or the official record.
Study officials
Erin F CobainPrincipal investigator · SWOG Cancer Research Network
Contacts are provided by the registry for study enquiries. Do not use these details for marketing or promotions.
FURTHER READING
Results, documents and references
No results are posted in this registry record
This does not mean the study has no findings. Results may not yet have been submitted or published here.
No study documents are listed in this record.